PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00401245
- Locations
Pfizer Investigational Site
Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development
- Conditions
- Healthy Subjects
- Interventions
- Procedure: Blood Collection
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 955
- Registration Number
- NCT00401232
- Locations
- 🇺🇸
Frontage Clinical Services Inc, Hackensack, New Jersey, United States
🇺🇸SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Open-label Extension Study Of RN624
- Conditions
- OsteoarthritisOA Knee PainArthritis
- Interventions
- Drug: RN624 (PF-04383119)
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 287
- Registration Number
- NCT00399490
- Locations
- 🇺🇸
Sports Medicine and Orthopaedics Center, Greensboro, North Carolina, United States
🇺🇸Office of Walter F. Chase, MD, PA, Austin, Texas, United States
🇺🇸Northwest Indiana Center for Clinical Research, Merrillville, Indiana, United States
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
- Conditions
- Obesity
- Interventions
- Drug: CP-945,598 Treatment BDrug: CP-945,598 Treatment ADrug: Placebo
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1253
- Registration Number
- NCT00396448
- Locations
- 🇬🇧
Pfizer Investigational Site, Northwood, Middlesex, United Kingdom
Safety Study In Patients Who Were Born Small And Short And Were Treated With Growth Hormone To Achieve Normal Height
- Conditions
- Infant, Small for Gestational Age
- Interventions
- Other: post GH treatment observational study
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00396474
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 316
- Registration Number
- NCT00396097
- Locations
- 🇺🇸
Central Ohio Pediatric Endocrinology/Diabetes Services (COPEDS), Columbus, Ohio, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Cooks Children Medical Center/Dept. of Pediatric Endocrinology, Fort Worth, Texas, United States
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
- Conditions
- Osteoarthritis
- Interventions
- Drug: placeboDrug: RN624 (PF-04383119)
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2009-10-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 450
- Registration Number
- NCT00394563
- Locations
- 🇺🇸
Pfizer Investigational Site, Yakima, Washington, United States
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 594
- Registration Number
- NCT00393939
- Locations
- 🇬🇧
Pfizer Investigational Site, Wolverhampton, United Kingdom
A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis
- Conditions
- Upper Respiratory Tract Infection
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 99
- Registration Number
- NCT00393835
- Locations
- 🇯🇵
Pfizer Investigational Site, Wakayama, Japan
Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne
- Conditions
- Acne Vulgaris
- Interventions
- Drug: minocycline-placebo capsules
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00392223
- Locations
- 🇮🇹
Pfizer Investigational Site, Trieste, Italy